|
Author(s): |
Yongqing Liu, Materials Science and Engineering Institute, Tianjin University of Science and Technology Tianjin, China/Institute of Medical Equipment, Academy of Military Medical Sciences Tianjin, China
Yongyan Cui, Materials Science and Engineering Institute, Tianjin University of Science and Technology Tianjin, China
Zhihong Li, Institute of Medical Equipment, Academy of Military Medical Sciences Tianjin, China
Jing Guan, Institute of Medical Equipment, Academy of Military Medical Sciences Tianjin, China
Xizheng Zhang, Institute of Medical Equipment, Academy of Military Medical Sciences Tianjin, China
Jimin Wu, Institute of Medical Equipment, Academy of Military Medical Sciences Tianjin, China |
|
Abstract: |
Controlled delivery of basic fibroblast growth factor (bFGF) for a long time could be used as an angiogenesis therapy. In this study, novel heparin-conjugated poly (L-lactide-co-glycolide) (PLGA) microspheres (HCPMs) were developed for long-term, zero-order delivery of bFGF. HCPMs were prepared using a coupling reaction between PLGA graft with Amino (PLGA-NH2) microspheres and heparin in the presence of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide. Modified collagen (M-collagen) was crosslinked using N-(3-dimethylaminopropyl)-N1-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The release of bFGF from HCPMs was sustained for 3 weeks. The bFGF release was increased to more than 4 weeks using a delivery system of HCPMs suspended in M-collagen. The release was nearly zero order. The bioactivity of bFGF released from HCPMs in M-collagen was assessed using human umbilical vein endothelial cell (HUVEC) culture. bFGF released from HCPMs in M-collagen exhibited HUVEC growth for 15 days, similar to that of cultures to which bFGF in free form was added daily, suggesting that the delivery system of HCPMs in M-collagen can release bFGF in a bioactive form for a long period. This study shows that a bFGF delivery system using HCPMs in M-collagen exhibits controllable, long-term, zero-order release of bFGF and potentiates the angiogenic efficancy of bFGF administration.
|